Sumitomo Dainippon Pharma
-
Artificial Intelligence, BioPharma
Sumitomo Schizophrenia Drug Discovered With AI Tech Fails in Two Phase 3 Trials
A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from a psychiatry and neurology collaboration spanning four drugs discovered by an artificial intelligence technology platform.
-
Sumitomo pays $3B to Vivek Ramaswamy’s Roivant under new alliance
The Sumitomo Dainippon-Roivant Alliance will be wholly owned by Sumitomo, which is also taking control of five companies – and potentially six more – from Ramaswamy’s Vant family of firms.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.